Ardelyx, Inc. - Common Stock (ARDX)

Revenue for the quarter was $116.13 million, topping the consensus estimate of $111.16 million, driven by robust sales of its two approved drugs, Ibsrela and Xphozah.

The biopharma reported strong revenue growth in the fourth quarter thanks to solid performances from both of its approved products, Ibsrela and Xphozah.

Stocks tumbled Thursday, with all major indices in the red, one day after the S&P 500 notched another all-time high in Wednesday’s trading session.

Ardelyx reported its third-quarter results after Thursday's closing bell. Here's a look at the details from the report:

These stocks are at a risk of providing negative returns to shareholders due to the several operational challenges faced by the companies.

Ardelyx challenges CMS in a lawsuit over Medicare's inclusion of Xphozah in bundled payments, affecting kidney disease drug accessibility.

Ardelyx shares are trading lower Tuesday after the company announced it has chosen not to apply to include XPHOZAH in the Centers for Medicare & Medicaid Services End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Transitional Drug Add-on Payment Adjustment.

Looking for volume plays? Here are three stocks under $10 that might just drive your earnings to millions in the next few years.

Though risky, investors who buy biotech stocks watch their portfolios skyrocket when their drugs work as intended.

Ride the momentum with these affordable penny stocks as they continue to display for solid profits this year.

Discover seven penny stocks poised for significant gains in 2024. Explore opportunities in cannabis, mining, EVs, and more.